Skip to main content

Nifty may touch 13,640 by December 2021: Nomura

Nomura also pointed out that the September quarter earnings have beaten expectations.

Global brokerage firm Nomura is of the view that Nifty may hit the level of 13,640 by December 2021.

Nomura is of the view that the improvement in sentiment around the pandemic and improving high-frequency growth indicators and corporate earnings as the economy opens up could lead to market overlooking potential growth concerns that can emerge over time.



"Factoring in 4-5 percent risk to FY22/23 consensus earnings estimates and using 19 times on December-22 earnings, we arrive at December-21 Nifty target of 13,640, implying upside of 7 percent from the current levels. Upside risk to our target multiple in the near-term remains, on the back of strong capital flows," said Nomura in a note on November 12.

Nomura thinks We think capital flows resulting from improved risk sentiment will drive stocks in the near term.

The foreign brokerage firm also highlighted that the market sentiment is high due to positive reports about the coronavirus vaccine.

"News on the vaccine front has been positive over the past few days. Pfizer and RDIF (more relevant for India) have announced that their vaccines under development have demonstrated the efficacy of over 90 percent, based on interim Phase III results. This has raised hopes of the COVID-19 pandemic being contained, if not eradicated, and normalcy gradually returning to people’s lives," said Nomura.

Nomura added that the development of vaccines furthers the objective of normalisation, as it holds out the prospect of preventing infection, limiting the spread and reducing infection severity.

The development is positive for equities, Nomura said, as it improves risk sentiment against the backdrop of strong liquidity and sustained capital flows.

Nomura also pointed out that the September quarter earnings have beaten expectations.

"The Q2 earnings season has provided stability to FY21/22 earnings expectations. Post the spread of the pandemic and economic lockdowns, consensus FY21/22 earnings for Nifty were revised down by 27 percent/15 percent in Q1FY21; however, forecasts seem to have found a near-term bottom, and since Q1FY21-end, earnings estimates have been raised by 3.5 percent/4 percent for FY21/22," said Nomura.

"Consensus is now factoring in a 20 percent earnings CAGR over FY20-23, compared to a 7 percent CAGR over FY15-19. We think expectations for medium-term earnings growth are high and are premised on a strong growth revival, lower costs (including multiyear-low credit costs for banks)," Nomura added.

The foreign brokerage firm, however, pointed out that there are potential risks to current earnings estimates, mainly a slower-than-expected revival in economic growth and the adverse impact of a rise in commodity prices.

"Currently, based on bottom-up analysis, we are factoring in 4-5 percent risk to current consensus estimates for FY22/FY23," said the brokerage.

Nomura has increased weight on banks and financials and is now overweight on financials.

"In our model portfolio, we raise the weight on financials, as we expect their valuations could expand on the expectation of improving growth rates. We increase our weight on banks (increase weight in ICICI Bank, Axis Bank, add State Bank of India and Max Financial)," said Nomura.

On the other hand, Nomura has reduced weight on IT and pharma.

"We have reduced our weight on IT and pharma, but continue to remain overweight on these sectors, as we expect multiples to expand as earnings visibility improves," said Nomura.

"We add Sun Pharma. Our top picks are ICICI Bank, Axis Bank, HCL Tech, Mahindra & Mahindra and Sun Pharma (all buy-rated)," Nomura said.

Disclaimer: The above report is compiled from information available on public platforms. SD Soutions advises users to check with certified experts before taking any investment decisions.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

  All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...
Post a Comment
Read more

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

  Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...
Post a Comment
Read more